Team name	Belarus
Team member(s) (firstnamelastname;)	Alexander Tuzikov , Alexander Andrianov, Yuri Kornoushenko, Hanna Karpenka, Ivan Bosko, Nikita Shuldov, Artsemi Yushkevich, Konstantin Furs
Affiliation	The National Academy of Sciences of Belarus
Contact email	rfe.karpenko@gmail.com
Contact phone number (optional)	+375296665458
Protein targets (for example: 3CLPro/Nsp5,	3CLpro (binded active site), 3CLpro (unbinded
BoAT1, Fc Receptor, Furin, IL6R, M protein, Nspx, OrfXx, N, E, etc)   3 required	active site), spike

#### Section 1: methods & metrics

Describe what methods you have used, how they are independent from one another, what your workflow was, how you performed the cross-correlation between your methods. If applicable, please report estimated performance metrics of your methods, such as accuracy, sensitivity, false-discovery rate, etc., and how those metrics were obtained (e.g. cross-validation). Please provide key references if available.

	Screening			
Pharmit provides an online (htt	p://pharmit.csb.pitt.edu/), interac	tive environment for the virtual		
screening of large compound	databases using pharmacophores	, molecular shape and energy		
	minimization.	,		
3CLpro (binded active site)	3CLpro (unbinded active site)	Spike		
The pharmacophore model was	The pharmacophore model was	The pharmacophore model was		
built on the basis of the	built on the basis of the	built on the basis of the		
interaction of the X77 inhibitor	interaction of the X77 inhibitor	interaction of Lys353 ACE2		
with the main protease SARS-	with the main protease SARS-	receptor residue with S1		
CoV2. Multiple pharmacophore	CoV2. Several pharmacophore	protein residues. The model		
models were created.	models were created. The first	includes one hydrogen donor,		
model includes three aromatic one hydrogen acceptor and				
	and one hydrophobic	three hydrophobic interactions.		
pharmacophore.				
The selected databases were s	earched for compounds that matc	h the specified pharmacophore		
using the Pharmer search tech	nnology. The best screening compo	ound was used to create a new		
pharmacophore model. A	repeated search was performed o	n the selected databases.		
Energy minimization of results w	was used to optimize both the pose	e and conformation of identified		
hits with respect to the provide	d receptor using the AutoDock Vin	a scoring function and smina, a		
fork of AutoDock Vina with enha	anced minimization functionality. N	Minimized results were sorted by		
	affinity.			
The complete set of 870000	The complete set of	The complete set of 17000		
minimized compound	870000 minimized compound	minimized compound		
structures was saved, including	structures was saved, including	structures was saved, including		
scoring annotations, as a	scoring annotations, as a	scoring annotations, as a		
compressed SDF structure file.	compressed SDF structure file.	compressed SDF structure file.		

Before docking, hydrogen atoms were added to the ligand and receptor structures and their optimization was performed in the UFF force field. For this purpose, the Open Babel program (http://openbabel.org/wiki/Main\_Page) was used.

3CLpro (binded active site)	3CLpro (unbinded active site)	Spike
Molecular docking of 870000	Molecular docking of 870000	Molecular docking of 17,000
compounds was performed	compounds was performed	compounds was performed
using the Quick Vina 2 program	using the Quick Vina 2 program	using the Quick Vina 2 program
(https://omictools.com/quickvi	(https://omictools.com/quickvi	(https://omictools.com/quickvi
na-tool) with a conformational	na-tool) with a conformational	na-tool) with a conformational
coverage parameter of 10.	coverage parameter of 10.	coverage parameter of 10.
	The dissociation constant for	
	the top 10,000 compounds was	
	converted from the binding	
	energies after docking.	
	The pharmacophore model was	
	built on the basis of the	
	interaction of the X77 inhibitor	

#### **Dynamics**

with the main protease SARS-

3CLpro (binded active site)/ 3CLpro (unbinded active site)

In the case of dynamic ligand MPro models, the values of binding energy were calculated with Amber18 using the MM/GBSA method. The calculations were made for 200 snapshots extracted from the final 40 ns of the MD trajectories, by keeping the snapshots every 0.2 ns. The polar solvation energies were computed in continuum solvent using Poisson-Boltzmann continuum-solvation model with ionic strength of 0.10. The non-polar terms were estimated using solvent accessible surface areas.

CoV2

Spike

*In the case of dynamic ligand* Spike S1 models, the values of binding energy were calculated with Amber18 using the MM/GBSA method. The calculations were made for 200 snapshots extracted from the final 40 ns of the MD trajectories (overall 50 ns), by keeping the snapshots every 0.2 ns. The polar solvation energies were computed in continuum solvent using Poisson-Boltzmann continuumsolvation model with ionic strength of 0.10. The non-polar terms were estimated using solvent accessible surface areas.

## ML

MACCS molecular fingerprints were obtained from SDF structure files and free binding energy was parsed using docking results. Fingerprints for each compound were matched with corresponding binding energy to form a dataset used for training of an adversarial generative autoencoder. The training was conducted in a semi-supervised manner, where fingerprints were fed to the encoder, while binding energy was fed to the special corresponding neuron on the latent layer, and decoder used both compressed representation obtained by encoder AND binding energy to restore original fingerprints. Latent layer was additionally discriminated with a normal distribution, to enforce

encoder to make meaningful compressed representation. Later, the model was used to generate new molecular descriptors (fingerprints) with a preset property of binding energy. Namely, in order to generate new fingerprints, numbers from normal distribution were sampled to the latent layer, while the neuron responsible for binding energy was given a threshold value to generate with (e.g. - 10 kkal/mol).

For the generated fingerprints a similarity search was conducted among ZINC library compounds, using L1 distance as a metric. Closest compounds were subjected to docking procedures. Rdkit python package was used for preprocessing, MACCS fingerprints generation. Tensorflow 2.1 for python was used as a deep learning framework.

#### Section 2: targets

Describe for each protein target: why you chose it, from which source you obtained it (e.g., insidecorona.net / covid.molssi.org / rcsb.org) and why this is the best quality structure, if any pre-processing (e.g., energy minimization, residue correction, alternative folding, ...) was performed.

## Target 1: 3CLpro (binded active site).

The main protease of the SARS-CoV2 virus (3CLpro) controls the maturation of viral proteins. Therefore, the ability to inhibit the activity of 3CLpro in order to block the stage of maturation of viral proteins is highly relevant.

The crystal structure of the 3CLpro protein in complex with the X77 inhibitor, determined by X-ray diffraction analysis, was borrowed from the protein data bank ((PDB) code 3W63; https://www.rcsb.org/structure/6W63).

The resolution of the complex is 2.10  $\mathring{A}$  and is the best for the complex 3CLpro / X77.

## Target 2: 3CLpro (unbinded active site)

The main protease of the SARS-CoV2 virus (3CLpro) controls the maturation of viral proteins. Therefore, the ability to inhibit the activity of 3CLpro in order to block the stage of maturation of viral proteins is highly relevant.

The crystal structure of the free 3CLpro protease form determined by x-ray diffraction analysis was taken from the protein database ((PDB) code 6Y84; https://www.rcsb.org/structure/6Y84). The resolution of the complex is 1.39 Å and is best for the unbound form of 3CLpro.

# Target 3: spike

Protein S1 is required for SARS-CoV2 penetration into sensitive cells. Therefore, its inhibition in order to block the stage of virus penetration is highly relevant.

The crystal structure of the S1 protein in complex with the ACE2 protein, determined by X-ray diffraction analysis, was taken from the protein database ((PDB) code 6MOJ; https://www.rcsb.org/structure/6MOJ).

For a complex of S1 protein with ACE2 protein, a resolution of 2.45 Å is one of the best found in PDB.

#### Section 3: libraries

Describe which libraries you have used, how they were combined, if any compounds were removed / added, why additions are relevant, any unique features of your library, etc. Please provide the sources you obtained the libraries from (if publicly available). Describe the procedure of data preparation (removal of duplicates, standardization, etc). Indicate if different libraries were used for different targets, and why. If possible, provide a download link to your version of the library.

All the libraries (Pubchem, Molport, ZINC, ChemDiv etc.), integrated into the Pharmit web server, were used for virtual screening.

### Section 4: results

Briefly describe you key findings, any interesting trends in your data, a description of your top 5 compounds for each target. If possible, provide a link to a code and/or data repository. Please do not submit randomly selected compounds!

#### Results:

<u>Results:</u>								
	TOP 5 3CLpro (binded active site)							
Data base	Ligand	Vina	NNScore2	Amber ∆H	Link			
ID		(kcal/mol	.0 (nm)	(kcal/mo				
		)		1)				
PubChem		-13.4	12.7	_	https://			
_				56.8±5.1	pubchem.			
1302582					ncbi.nlm			
90	s N				.nih.gov			
	N N				/compoun d/130258			
	(_)~n "				290			
					= 3 3			
	N							
PubChem		-13.4	3.9	_	https://			
-	O N			62.8±5.1	pubchem.			
1224895					ncbi.nlm			
0.3	N				.nih.gov /compoun			
					$\frac{7 \text{ Compoun}}{d/122489}$			
					503			
	o N							
	N							
	( )							

			T		
PubChem		-13.9	326.5	_	https://
_				62.4±4.2	pubchem.
1302585					ncbi.nlm
75					.nih.gov
	N				/compoun
					<u>d/130258</u>
					<u>575</u>
PubChem		-13.6	4.2	_	https://
_				59.3±4.4	pubchem.
1302582					ncbi.nlm
93					.nih.gov
	0				/compoun
	N N				d/130258
					293
	ý				
PubChem		-10.0	0.034	-56.2 ±	https://
- ubchem		10.0	0.034	3.1	pubchem.
5915818				J•1	ncbi.nlm
7	_N_				nih.gov
,	~ <b>o</b>				/compoun
	N. A. O. A. N.				d/591581
					87
	O				<u> </u>
	N				
	н "				
	F				
	CI				
1					

TOP 5 3CLpro (unbinded active site)					
Data base	Ligand	Vina	NNScore2	Amber ΔH	Link
ID		(kcal/mol	.0 (nm)	(kcal/mo	
		)		1)	

PubChem - 1224663 16	-11.5	2.0	-53.6 ± 6.0	https:// pubchem. ncbi.nlm nih.gov /compoun d/122466 316
PubChem - 1351638 06	-11.7	22.5	-58.7 ± 8.6	https://pubchem.ncbi.nlm.nih.gov/compound/135163
PubChem - 1183281 52	-11.4	3.8	-59.4 ± 4.3	https://pubchem.ncbi.nlm.nih.gov/compound/118328

CHEMBL1 813644	S N N H O N N H O N N H O N N N N N N N N	-8.9	0.014	-58.3 ± 7.2	https://www.ebi.ac.uk/chembl/compound report card/CHEMBL1813644/
PubChem - 2432911 7	Z-Z 0 0 0 L	-8.2	0.059	-57.1 ± 4.4	https:// pubchem. ncbi.nlm .nih.gov /compoun d/243291 17
	TOP	5 Spike			
Data base ID	Ligand	Vina (kcal/mol )	NNScore2 .0 (nm)	Amber ΔH (kcal/mo	Link
PubChem - 1375518 23	F NN N N N N N N N N N N N N N N N N N	-12.6	479410.0 0	-45.1 ± 5.7	https:// pubchem. ncbi.nlm .nih.gov /compoun d/137551 823

PubChem - 1105144 6	F F F F F F F F F F F F F F F F F F F	-10.2	1.23	-37.9 ± 4.2	https:// pubchem. ncbi.nlm nih.gov /compoun d/110514 46
PubChem		-9.6	32000	-48.1 ±	https://
- 8926937 9	THE REPORT OF THE PART OF THE			5.3	pubchem. ncbi.nlm .nih.gov /compoun d/598475 33
PubChem - 1099679 6	F F F F F F F F F F F F F F F F F F F	-10.0	0.978	-37.9 ± 3.5	https:// pubchem. ncbi.nlm .nih.gov /compoun d/109967 96

PubChem		-9.5	3210	-44.0 ±	https://
_				3.6	pubchem.
5984753					ncbi.nlm
3	- /0 0				.nih.gov
	HI I I NH				/compoun
	OHN H				d/892693
	H >0				79
	LINE AND				
	O H H O				
	, , , , , ,				

Other comments: